Lilly’s Oral GLP-1 Push Gains Momentum. Can Foundayo Become its Next Growth Engine?

Eli Lilly and Company (NYSE:LLY)’s CEO David Ricks told CNBC that Foundayo now accounts for roughly one-third of new patients starting an oral GLP-1, with Lilly’s share of the pill market increasing week over week. The update comes as Lilly broke ground on a $6.5 billion manufacturing facility in Houston that is expected to be operational by 2030 and will produce Foundayo and other small-molecule medicines. Lilly also plans to launch Foundayo in additional international markets.

The early commercial traction is meaningful because Foundayo generated $98 million in second-quarter revenue after launching in April. Lilly’s total revenue reached $23.0 billion in Q2, up 48% year over year, while the company raised its 2026 revenue guidance to $85 billion-$87 billion.

Also read: Foundayo’s Early Growth Is Raising Lilly (LLY)’s Revenue Expectations. But Can It Outrun Pricing Pressure?

Foundayo’s Growing Share Could Give Lilly Another Major Growth Driver

Foundayo could give Eli Lilly and Company another major growth engine in obesity while expanding the overall GLP-1 market. Lilly previously reported that about 80% of early Foundayo prescriptions were from patients new to the GLP-1 category, suggesting the pill is not simply shifting existing Zepbound users from injections. Reuters has also reported that oral GLP-1 drugs could capture as much as 40% of the market as pills attract patients who are reluctant to use injections.

The product also has characteristics that could support adoption. Foundayo can be taken once daily without food or water restrictions, while Lilly’s clinical data showed up to 13% average weight reduction at the highest approved dose among adults aged 65 and older. Lilly has also reported that Foundayo outperformed oral semaglutide in a head-to-head diabetes trial on both A1C reduction and weight loss.

Lilly is building capacity ahead of potential demand rather than waiting for supply constraints to emerge. The company has already undertaken significant manufacturing expansion, including an additional $4.5 billion commitment to Indiana facilities, while the Houston project adds another $6.5 billion of long-term capacity. If Foundayo’s market share continues rising and international launches broaden its reach, those investments could support larger volumes and extend Lilly’s cardiometabolic growth beyond Zepbound and Mounjaro.

Foundayo Faces a Tougher Test as Oral GLP-1 Competition Accelerates

Foundayo’s current contribution remains small relative to Eli Lilly and Company’s existing GLP-1 franchise. The pill generated only $98 million in Q2, while Mounjaro generated $9.94 billion and Zepbound generated $4.93 billion. Mounjaro and Zepbound together represented 65% of Lilly’s revenue during the first half of 2026, meaning the company’s near-term financial performance remains heavily dependent on its injectable products.

Competition is also intensifying rapidly. Novo Nordisk entered the oral market before Lilly, and its Wegovy pill had captured an estimated 90% of the U.S. oral market as of August, although Lilly has been gaining share. Reuters also reported that Novo’s next-generation CagriSema produced 12.4% average weight loss in a late-stage diabetes trial versus 9.1% for Lilly’s 5-mg tirzepatide dose in that study, underscoring the pace of competition in obesity medicines.

There is also a substantial capital commitment behind Lilly’s capacity expansion. Lilly spent $7.8 billion on capital expenditures in 2025 and said those investments would result in meaningfully higher capital expenditures in the near term. The company also warned that changes in incretin demand and channel dynamics can have a disproportionate effect on results.

Conclusion

The Foundayo update strengthens Eli Lilly and Company’s long-term growth opportunity because the pill is gaining new patients while Lilly expands manufacturing and prepares international launches. The $98 million Q2 contribution is still modest, but the early adoption indicators and expanding oral GLP-1 market provide a potential avenue for growth beyond the company’s highly concentrated Mounjaro-Zepbound franchise.

The key uncertainty is whether Lilly can sustain Foundayo’s market-share gains against Novo and convert growing demand into sufficiently profitable volume to justify its substantial manufacturing investments.

READ NEXT: AMD’s $1 Trillion Valuation Raises the Bar for its AI Ambitions and Oracle’s AI Expansion Faces a New Test as Data Center Costs Rise

This article is originally published at Insider Monkey.